All In Biotech

Drug Trial Radar · NCT05069740

Endometriosis and Microvascular Dysfunction: Role of Inflammation

Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Endometriosis

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jan 1, 2022

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Penn State UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Crossover
Masking
Single (investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to better understand the underlying mechanisms associated with elevated cardiovascular disease risk in women with endometriosis, and to measure the effectiveness of emerging endometriosis treatments on outcomes specific to cardiovascular dysfunction. Epidemiologic data demonstrate a clear association between endometriosis, reproductive risk factors, inflammation and cardiovascular (CV) risk. Circulating factors, low-density lipoprotein (LDL) and oxidized LDL (oxLDL), are two of many biomarkers of cardiovascular and inflammatory disease of endometriosis. An important signaling mechanism through which circulating LDL and oxLDL act is the lectin-like oxidized LDL receptor (LOX-1). LOX-1 signal transduction functionally results in pronounced endothelial dysfunction, a hallmark of CV. The investigators hypothesis that one factor mediating the elevated risk of cardiovascular disease in endometriosis is systemic inflammation and activation of LOX-1 receptor mechanisms.

Conditions

  • Endometriosis

Interventions

  • Salsalate PillDrug

    Salsalate acts as an NFkB inhibitor to reduce systemic inflammation

  • PlaceboDrug

    Placebo for the salsalate intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. cutaneous vascular conductanceTime frame: 5 days after treatment
  2. brachial artery diameter and blood flow velocityTime frame: 5 days after treatment
  3. Sera LOX-1 protein expressionTime frame: 5 days after treatment
  4. Biopsy LOX-1 protein expressionTime frame: 5 days after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Pennsylvania State University

    University Park, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.